Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
  • [21] Incidence of venous thromboembolism and association with PD-L1 expression in advanced non-small cell lung cancer patients treated with first-line chemo-immunotherapy
    De Azevedo, Liliana Aguiar
    Orione, Charles
    Tromeur, Cecile
    Couturaud, Francis
    Descourt, Renaud
    Geier, Margaux
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [22] Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab
    Trestini, I.
    Cintoni, M.
    Caldart, A.
    Dodi, A.
    Sposito, M.
    Kadrija, D.
    Belluomini, L.
    Menis, J.
    Vita, E.
    Sperduti, I.
    Drudi, A.
    Aluffi, G.
    Todesco, M.
    Tregnago, D.
    Avancini, A.
    D'Onofrio, M.
    Mele, M. C.
    Tortora, G.
    Milella, M.
    Bria, E.
    Pilotto, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S504 - S505
  • [23] Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
    Jin, Chen-xing
    Liu, Yan-song
    Qin, He-nan
    Teng, Yi-bin
    Sun, Rui
    Ma, Zhong-jing
    Wang, A-man
    Liu, Ji-wei
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [24] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [25] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
    Stares, Mark
    Doyle, Emma
    Chapple, Sally
    Raynes, George
    MacDonald, James
    Barrie, Colin
    Laird, Barry
    MacKean, Melanie
    Philips, Iain
    LUNG CANCER, 2024, 189
  • [26] Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy
    Kang, Min Kyu
    Lee, Shin Yup
    Choi, Jin Eun
    Do, Sook Kyung
    Cho, Moon-June
    Kim, Jun-Sang
    Park, Jae Yong
    CANCER MEDICINE, 2021, 10 (22): : 8071 - 8078
  • [27] PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
    Miyawaki, Eriko
    Murakami, Haruyasu
    Mori, Keita
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (05) : 617 - 622
  • [28] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [29] Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
    Li, Mingjia
    Zhao, Songzhu
    Lopez, Gabrielle
    Secor, Austin
    Das, Parthib
    Surya, Nitya
    Grogan, Madison
    Patel, Sandip
    Chakravarthy, Karthik
    Miah, Abdul
    Spakowicz, Daniel
    Tinoco, Gabriel
    Li, Zihai
    Wei, Lai
    He, Kai
    Bertino, Erin
    Alahmadi, Asrar
    Memmott, Regan
    Kaufman, Jacob
    Shields, Peter G.
    Carbone, David P.
    Presley, Carolyn J.
    Otterson, Gregory A.
    Owen, Dwight H.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2067 - 2074
  • [30] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Kawachi, Hayato
    Tamiya, Motohiro
    Tamiya, Akihiro
    Ishii, Seigo
    Hirano, Katsuya
    Matsumoto, Hirotaka
    Fukuda, Yasushi
    Yokoyama, Toshihide
    Kominami, Ryota
    Fujimoto, Daichi
    Hosoya, Kazutaka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kanazu, Masaki
    Sawa, Nobuhiko
    Uchida, Junji
    Morita, Mitsunori
    Makio, Takeshi
    Hara, Satoshi
    Kumagai, Toru
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218
12345